Axa lifted its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 63.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 250,356 shares of the medical research company’s stock after purchasing an additional 96,925 shares during the period. Axa owned about 0.12% of Edwards Lifesciences worth $43,587,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC raised its stake in Edwards Lifesciences by 32.9% during the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock worth $977,456,000 after acquiring an additional 1,663,511 shares in the last quarter. Brown Advisory Inc. raised its stake in Edwards Lifesciences by 5.8% during the 2nd quarter. Brown Advisory Inc. now owns 3,866,016 shares of the medical research company’s stock worth $562,775,000 after acquiring an additional 211,258 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Edwards Lifesciences by 5.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock worth $312,614,000 after acquiring an additional 107,676 shares in the last quarter. Jennison Associates LLC raised its stake in Edwards Lifesciences by 70.8% during the 3rd quarter. Jennison Associates LLC now owns 1,444,384 shares of the medical research company’s stock worth $251,467,000 after acquiring an additional 598,735 shares in the last quarter. Finally, Morgan Stanley raised its stake in Edwards Lifesciences by 38.4% during the 2nd quarter. Morgan Stanley now owns 1,329,458 shares of the medical research company’s stock worth $193,531,000 after acquiring an additional 369,027 shares in the last quarter. 81.27% of the stock is owned by institutional investors and hedge funds.

EW has been the topic of several research analyst reports. Barclays initiated coverage on shares of Edwards Lifesciences in a research note on Monday, October 15th. They set an “underweight” rating and a $143.00 price target on the stock. Northland Securities reiterated a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a research note on Thursday, October 11th. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Wednesday, September 26th. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. Finally, ValuEngine lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $156.79.

NYSE EW opened at $149.59 on Wednesday. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $32.55 billion, a price-to-earnings ratio of 39.37, a price-to-earnings-growth ratio of 2.05 and a beta of 0.87. Edwards Lifesciences Corp has a one year low of $107.49 and a one year high of $175.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.05. The company had revenue of $906.60 million for the quarter, compared to analyst estimates of $927.56 million. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. Edwards Lifesciences’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.84 earnings per share. Equities analysts anticipate that Edwards Lifesciences Corp will post 4.7 earnings per share for the current year.

In other news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $150.88, for a total value of $4,963,952.00. Following the sale, the chief executive officer now owns 76,026 shares of the company’s stock, valued at $11,470,802.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Huimin Wang sold 3,800 shares of Edwards Lifesciences stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $141.73, for a total transaction of $538,574.00. Following the completion of the sale, the vice president now directly owns 77,865 shares in the company, valued at approximately $11,035,806.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 203,089 shares of company stock worth $29,650,650. 1.84% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2018/11/21/edwards-lifesciences-corp-ew-stake-raised-by-axa.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: Technical Analysis of Stocks and What It Means

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.